Home>Topics>Companies>Johnson & Johnson

Johnson & Johnson JNJ

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
    1. Building my 'Income Builder' Portfolio / Good bye JNJ - hello GSK

      Commentary

      Wed, 23 Jul 2014

      Balanced funds thread examined income builder funds and specifically Thornburg Income Builder. I'll let that rest. I sold JNJ recently when it topped 100 - had a great gain - love the company and the industry - but don't like the ~2.7 yield

    2. HIV combo therapy candidate fails Phase 3

      Headlines

      Tue, 22 Jul 2014

      a Phase 3 trial comparing a once-daily dose of Solzentry ( maraviroc ) ( PFE +0.7% ) with Prezista (darunavir) ( JNJ +1.1% ) and Norvir (ritonavir) ( ABBV +0.2% ) to emtricitabine / tenofir with darunavir plus ritonavir (DRV

    3. Bovie Medical: Little Bovie May Be Running With The Big Dogs

      Headlines

      Tue, 22 Jul 2014

      By Andrew Stephan : Although a very small company by Wall Street standards, Bovie Medical Corporation (NYSEMKT: BVX ) has been developing very promising new medical device technologies that could have major impacts on some important areas in the healthcare industry, such as surgery and wound care.

    4. Johnson & Johnson to buy back shares

      Headlines

      Mon, 21 Jul 2014

      The BOD of J & J ( JNJ -0.5% ) authorizes the repurchase of up to $5B of the company's common stock. Shares will be bought at management's discretion

    5. Medivation Significantly Undervalued, With Xtandi Weeks Away From Prostate Cancer Label Expansion

      Headlines

      Mon, 21 Jul 2014

      By Stock Doctor : Investors in biotechnology stocks, including myself, are always trying to balance risk and reward when purchasing stocks in this highly volatile sector. Having a biomedical Ph.D., I spend endless hours poring over data looking for underappreciated stocks with significant upside ...

    6. Johnson & Johnson declares $0.70 dividend

      Headlines

      Mon, 21 Jul 2014

      Johnson & Johnson ( NYSE : JNJ ) declares $0.70/share quarterly dividend , in line with previous. Forward yield 2.77% Payable Sept. 9; for shareholders of record Aug. 26; ex-div Aug. 22. Post your comment!

    7. Retirement Strategy: Grow Your Income Without Spending More Money

      Headlines

      Sat, 19 Jul 2014

      How I Do It The BTDP consists of the following stocks: AT&T (NYSE: T ), Exxon Mobil (NYSE: XOM ), Johnson & Johnson ( NYSE : JNJ ), Coca-Cola (NYSE: KO ), Procter & Gamble (NYSE: PG ), Altria (NYSE: MO ), McDonald's (NYSE

    8. The Friday Five

      Video Reports

      Fri, 18 Jul 2014

      TICKER: JNJ ] Johnson & Johnson came in with a pretty ..... our [TICKER: JNJ ] Johnson & Johnson analyst, really ..... which helps give J & J some price protection ..... because [TICKER: JNJ ] Johnson & Johnson 's device business

      J J found at 5:15

      keep them there for some time. So Colello views this deal positively. Benz: [TICKER: JNJ ] Johnson & Johnson came in with a pretty strong quarter. Glaser: They had nice results, and it was really driven by their pharmaceutical part of their business and their hepatitis C treatment that's doing very well. Now that particular treatment is going to face some competition in the coming years from other companies, so that growth will moderate. But they have a pretty strong pipeline, and Damien Conover, our [TICKER: JNJ ] Johnson & Johnson analyst, really sees that their patent losses are pretty manageable. [Those patent losses] tend to be in products that would actually be difficult to produce for generic versions of which helps give J & J some price protection there, and that pharmaceutical group should continue to drive earnings. This is particularly important because [TICKER: JNJ ] Johnson & Johnson's device business is not doing great right now, and their consumer business is really still rebounding off of the some issues in manufacturing, the recall issues they had recently, so really pharmaceuticals are driving that story right now. Benz: So I know at one point a few years ago all the pharma stocks looked pretty cheap to us, how about right now, especially J & J ? Glaser: Yeah, let's keep this theme going. We just aren't seeing a lot of value in those names. There's a few--Baxter looks
    9. Morningstar's Most Popular

      Headlines

      Fri, 18 Jul 2014

      Stock Quotes Apple IBM Intel General Electric AT&T Most Requested Stock Analyses Exelixis Apple Intel Wells Fargo Johnson & Johnson Most Requested Fund Quotes Fidelity Contrafund Vanguard Wellington Vanguard Dividend Growth Vanguard 500 Index Dodge

    10. New Morningstar Analyst Report for Stryker Corporation

      Stock Reports

      Fri, 18 Jul 2014

      Orthovita to bulk up its orthobiologic offerings. Based on Lobo's previous experiences, which included time at Johnson & Johnson ’s McNeil division and Ethicon Endosurgery, we expect his facility with health care to serve him well at Stryker

    « Prev12345Next »
    Content Partners